Inhibikase Therapeutics Inc. (IKT)
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IKT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $185.16M
- EPS (TTM)
- -$0.40
- Dividend yield
- None
- 52-week range
- 1.28 – 2.61
- Day range
- 1.28 – 1.37
- Volume / Avg
- 1.11M / 584.27K
- Beta
- —
- Shares outstanding
- 140.27M
52-week range
IKT stock today
Inhibikase Therapeutics (IKT) closed at $1.32 on Nov 20, up 1.54% (+$0.02), versus the S&P 500's 3.70% decline. At this level, IKT sits near the bottom of its 52-week range of $1.28 to $2.61: 49.4% below the high, set on Sep 3, 2026 and 3.1% above the low. IKT is down 35.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.4%.
Inhibikase Therapeutics has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Inhibikase Therapeutics
Company profileInhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Mark T. Iwicki
- Headquarters
- Wilmington, DE
- Employees
- 35
- IPO year
- 2020
- Website
- inhibikase.com
Financial highlights
Full financialsInhibikase Therapeutics reported a net loss of $48.3 million, compared with a loss of $27.5 million a year earlier. Diluted earnings per share came in at -$0.49.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $260.50K | $123.44K | $3.10M |
| Growth | — | -100.00% | +111.03% | -96.02% | +343.92% |
| Net income | $-48.26M | $-27.52M | $-19.03M | $-18.05M | $-14.79M |
| EPS (diluted) | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-0.81 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$5.55+320.45%
- Strong buy 1
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.10 vs $-0.11
- Surprise
- +9.09%
IKT news
All IKT newsInhibikase Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs IKT |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs IKT |
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs IKT |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs IKT |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs IKT |
| PALIPalisade Bio Inc. | 0.8399 | -9.24% | $150.74M | vs IKT |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs IKT |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs IKT |
Indexes, lists and sector
Inhibikase Therapeutics stock FAQ
What is Inhibikase Therapeutics's stock price today?
IKT last traded at $1.32 as of Nov 20, 4:00 PM EST, up 1.54% on the day. Prices are delayed at least 15 minutes.
Does Inhibikase Therapeutics pay a dividend?
No. Inhibikase Therapeutics does not currently pay a regular cash dividend.
Who is Inhibikase Therapeutics's CEO?
Mr. Mark T. Iwicki is the chief executive officer of Inhibikase Therapeutics Inc., which has about 35 employees.
Has IKT ever split its stock?
Yes. The most recent IKT stock split was a 1-for-6 split on Jun 30, 2023.
What is the IKT 52-week high?
The 52-week high for IKT is $2.61 and the 52-week low is $1.28. The stock is currently 49.4% below its high.